Katarzyna Wójcik‐Pszczoła

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 297 citations · Full text

Medicine, Clinical Sciences, Immunology +17

An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis

Tomasz Stompór, Mieczysław Pasowicz, Władysław Sułowicz et al. · American Journal of Kidney Diseases · 2002 · 164 citations

Medicine, Clinical Sciences, Nephrology +17

SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains

Tomasz Rzymski, Michał Mikuła, Eliza Żyłkiewicz et al. · Oncotarget · 2017 · 107 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 92 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 83 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +15